APA (7th ed.) Citation

Babic, G., Kameda, H., Alten, R., Batko, B., Hala, T., Radominski, S. C., . . . Cohen, S. (2019). Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: Efficacy, safety and immunogenicity from week 30 to week 54. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Babic, Goran, et al. Randomised, Double-blind, Phase III Study Comparing the Infliximab Biosimilar, PF-06438179/GP1111, with Reference Infliximab: Efficacy, Safety and Immunogenicity from Week 30 to Week 54. BMJ Publishing Group, 2019.

MLA (9th ed.) Citation

Babic, Goran, et al. Randomised, Double-blind, Phase III Study Comparing the Infliximab Biosimilar, PF-06438179/GP1111, with Reference Infliximab: Efficacy, Safety and Immunogenicity from Week 30 to Week 54. BMJ Publishing Group, 2019.